Watson Pharmaceuticals (WPI) Files ANDA for Generic SEASONIQUE
Tweet Send to a FriendGet Alerts WPI Hot Sheet
Up)
Trade WPI Now!
Watson Pharmaceuticals, Inc. (NYSE: WPI) confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.15 mg/0.03 mg) extended-cycle oral contraceptive product, prior to the expiration of patents owned by Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. Watson's levonorgestrel and ethinyl estradiol product is a generic version of Barr's (NYSE: BRL) SEASONIQUE.
Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacture, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products.
Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacture, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products.
You May Also Be Interested In
- CryoLife (CRY) Conditionally Approved to Start PerClot Trials in U.S.
- Bristol-Myers (BMY), AstraZeneca (AZN) SAVOR-TIMI-53 Misses Primary Efficacy Endpoint in Phase 4
- Boston Scientific (BSX) Implements Vercise DBS in INTREPID Trial
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
